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Purpose: To evaluate the results of intravitreal expansile gas injection, with or 
without recombinant tissue plasminogen activator (rtPA), followed by intravitreal 
bevacizumab injection for treatment of submacular hemorrhage (SMH) secondary 
to neovascular age-related macular degeneration (AMD).
Methods: In this interventional case series, 5 eyes of 5 patients with SMH secondary 
to choroidal neovascularization (CNV) due to neovascular AMD were treated with 0.3 
cc intravitreal SF6 (and 50 µg of rtPA in two eyes), followed by face-down positioning; 
24 hours later, 1.25 mg of bevacizumab was injected intravitreally. Main outcome 
measures included displacement of SMH and best corrected visual acuity (BCVA).
Results: Mean patient age was 75.6±9.2 (range, 60-83) years, mean duration of symptoms 
was 6.4±3.2 (range, 3-10) days, and mean number of bevacizumab injections was 
1.8 (range, 1-3). Mean preoperative BCVA was 1.28±0.27 logMAR which improved 
significantly to 0.57±0.33 logMAR at 12 months (P=0.042). SMH displacement occurred 
in all eyes, and visual acuity improved and remained stable during the follow-up 
period of 12 months.
Conclusion: Intravitreal expansile gas injection, with or without rtPA, followed 
by intravitreal bevacizumab injection, seems to be an effective modality for SMH 
displacement and treatment of the underlying CNV in neovascular AMD.
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INTRODuCTION
Thick  submacular  hemorrhage  (SMH), 
particularly in patients with neovascular 
age-related macular degeneration (AMD), is 
generally associated with poor visual prognosis. 
Retrospective natural history studies have 
demonstrated that final visual acuity (VA) in AMD 
patients with thick blood beneath the fovea is 
rarely better than 20/200.1-4 Several mechanisms, 
including shearing of photoreceptors by fibrin 
clots, physical separation of the photoreceptors 
from the retinal pigment epithelium and iron 
toxicity have been suggested as explanations 
for retinal damage caused by thick subretinal 
blood.5-7 Natural history and experimental data 
have prompted the search for a safe and effective 
method of removing the blood from beneath the 
macula to hasten visual recovery and prevent 
irreversible damage to the outer retina.7-12 There 
is no standard treatment for acute SMH; the 
effectiveness of various treatment approaches is Expansile Gas and IVB for SMH; Nourinia et al
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difficult to evaluate and final VA depends to a 
great extent on the cause and extent of macular 
pathology. Advances in vitreoretinal surgery 
have made the removal of submacular blood 
possible, but surgical intervention is associated 
with various complications.
Several reports have demonstrated the 
ability of an intravitreal gas bubble, with13-  16 
or without17,18 intravitreal recombinant 
plasminogen activator (rtPA), to displace thick 
blood from beneath the fovea in most eyes. 
Visual improvement is often limited by the 
initial location and progression of the choroidal 
neovascularization (CNV), regardless of the 
technique used to treat SMH. Therefore, early 
diagnosis and treatment of the underlying 
cause of SMH may be the key to improving 
visual outcomes. Bevacizumab, a pan-VEGF 
inhibitor, has been demonstrated to possess 
the ability to reduce vascular leakage and 
inhibit growth of the CNV and has been widely 
adopted for treatment of neovascular AMD.19 
We hypothesized that intravitreal application 
of gas, with or without rtPA, supplemented 
by bevacizumab, would be beneficial in eyes 
with SMH due to neovascular AMD.
METHODS
This non-randomized interventional case series 
includes 5 eyes with SMH due to neovascular 
AMD that received intravitreal injection of 
expansile gas with or without rtPA followed 
by bevacizumab. Pre- and postoperative 
ophthalmologic examinations included 
determination of best corrected VA using a 
Snellen chart, slitlamp biomicroscopy, and 
indirect ophthalmoscopy. All patients were 
examined preoperatively and were followed for 
12 months after the procedure. Color fundus 
photography, fluorescein angiography (FA), 
and optical coherence tomography (OCT) 
were performed. All SMHs were of sufficient 
thickness to induce significant elevation of 
the entire neurosensory retina, completely 
obscuring the underlying choroidal vascular 
pattern on biomicroscopic examination. Each 
patient gave informed consent to this novel 
treatment approach after the nature of the 
disease, its natural course and alternative 
treatment modalities had been explained.
The procedure was performed under sterile 
conditions in the operating room. Intravitreal 
injection was performed 3.75 mm and 3 mm 
behind the limbus in phakic and pseudophakic 
eyes, respectively, using a #30 gauge needle. 
First, commercial rtPA, a lyophilized material, 
was diluted with balanced salt solution to a 
concentration of 1 mg⁄ml in polypropylene 
syringes. Then, 0.05 ml of the preparation, 
equal to 50 µg rtPA, was injected intravitreally. 
Subsequently, 0.3 ml of pure sulfur hexafluoride 
(SF6) gas was injected into the vitreous cavity. All 
patients were instructed to maintain face-down 
position until the next day. Twenty-four hours 
later, intravitreal injection of 1.25 mg/0.05 ml 
bevacizumab was performed in a similar fashion 
and under the same setting as described above.
Patients  received  reinjection(s)  of 
bevacizumab when recurrent CNV was 
noticed. Recurrence was defined as a decrease 
in VA associated with new foci of subretinal 
hemorrhage or intraretinal fluid detected by 
OCT, and leakage noted by FA.
RESuLTS
Patient characteristics are shown in Table 1. 
Mean age was 75.6±9.18 years (range, 60-83 
years) and mean duration of symptoms was 
Case Age (years)
Duration of 
symptoms (days)
Treatment
Preoperative VA 
(logMAR)
Final VA (logMAR)
Case 1 80 3 SF6+rtPA+IVB 1 0.18
Case 2 83 3 SF6+IVB 1.3 0.7
Case 3 80 7 SF6+rtPA+IVB 1.5 0.7
Case 4 60 9 SF6+IVB 1.6 1
Case 5 75 10 SF6+IVB 1 0.3
Table 1. Patient characteristics
VA, visual acuity; SF6, sulfur hexafluoride; rtPA, recombinant tissue plasminogen activator; IVB, intravitreal bevacizumabExpansile Gas and IVB for SMH; Nourinia et al
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6.4±3.2 days (range, 3-10 days). Successful 
inferior  displacement  of  the  SMH  was 
achieved in all (5/5) eyes. The mean number 
of bevacizumab injections was 1.8 (range, 
1-3). Mean preoperative VA was 1.28±0.27 
logMAR, which improved significantly to 
0.57±0.33 logMAR at 12 months (P =0.042). No 
complications related to intravitreal injection 
of gas, rtPA, or bevacizumab occurred during 
the follow-up period.
Case 1 is presented below as an example 
of the subjects.
Case 1
An 80-year-old male patient had been under 
observation for dry-type AMD in his left eye. 
There was history of severe vision loss in the 
right eye due to a disciform scar secondary to 
AMD since 1995. VA in his left eye had been 
20/25 with confluent soft drusen in the macula. 
In September 2006, he noticed sudden visual loss 
to 20/200. Ophthalmoscopy disclosed subretinal 
hemorrhage in the macular region (Fig. 1). 
Fluorescein angiography showed fluorescein 
blockage due to submacular hemorrhage (Fig. 2). 
An intravitreal injection of 50 µg rtPA and 0.3 
ml SF6 was performed promptly, followed by 
prone positioning for 24 hours. Displacement 
of subretinal hemorrhage was apparent the 
next day and intravitreal injection of 1.25 mg 
bevacizumab was performed. Due to persistent 
leakage on FA, a second injection of the same 
dose of bevacizumab was performed one month 
later. Follow-up examinations were performed at 
six-week intervals using OCT. The patient was 
followed for one year; at final examination the 
CNV regressed and best corrected VA reached 
20/30 (Figures 3, 4, 5).
Figure 1.  Color  photograph  of  the  left  eye  of  case  #1 
before treatment reveals submacular hemorrhage.
Figure 2. Fluorescein angiogram of the same eye as in 
figure  1  before  treatment  demonstrates  fluorescein 
blockage due to submacular hemorrhage.
Figure 3.  Color  photograph  of  the  left  eye  of  case  #1 
demonstrates resolved submacular hemorrhage without 
scar formation 12 months after treatment.Expansile Gas and IVB for SMH; Nourinia et al
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DISCuSSION
In this small case series, intravitreal injection 
of expansile gas with or without rtPA injection 
and followed by bevacizumab, proved successful 
in anatomical displacement of SMH and was 
associated with visual improvement. Mean 
preoperative VA was 1.28±0.27 logMAR which 
improved significantly to 0.57±0.33 logMAR 
at 12 months.
The visual outcome of AMD patients with 
submacular hemorrhage is typically poor, 
particularly in eyes with thick blood clots or 
those involving large areas of the macula and 
in the presence of a choroidal neovascular 
membrane. The size of the CNV and the amount 
of remaining SMH affect the volume of the 
disciform scar. Four reports have been published 
describing the natural course of submacular 
hemorrhage.1-4 Bennet and colleagues1 reported 
29 patients with submacular hemorrhage; mean 
initial VA was 20/1300 and mean final VA was 
20/1700. During follow-up, VA deteriorated or 
remained at the same level in all eyes. Avery 
and coworkers3 retrospectively reviewed a 
larger number of patients who had submacular 
hemorrhage secondary to AMD. Follow-up 
analysis was carried out at 12 and 36 months. 
Forty-one eyes were initially examined; after 
12 months, 23 eyes were examined, and at 36 
months only 15 eyes were evaluated. Mean 
initial VA was 20/200. By 36 months, 44% lost 
6 or more lines of VA, 22% lost 2 to 5 lines, 
12% retained vision within 1 line, and 21% 
showed spontaneous improvement of 2 or 
more lines. Of the group that improved, the 
most significant improvement occurred during 
the first 12 months, but even in this group 
vision deteriorated with longer follow-up. The 
largest series to date reviewed 60 eyes with 
submacular hemorrhage and AMD.4 As in prior 
studies, VA and the size and elevation of the 
Figure 5. Post-treatment OCT image of the macula in the 
left eye of case #1 reveals no subretinal or intraretinal 
fluid 12 months after intervention.
(a) (b)
Figure 4. Fluorescein (a) and indocyanine green (b) angiography shows an inactive choroidal neovascular lesion 12 
months after treatment in the left eye of case #1.Expansile Gas and IVB for SMH; Nourinia et al
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hemorrhage were examined. Mean initial VA 
was 20/240 and mean VA of all 60 eyes after 
24 months was 20/1250. Vision deteriorated 
in 80% of cases. Time for disappearance of the 
hemorrhage ranged from 2 to 18 months, with 
an average of 6 months.4 These studies support 
the clinical impression that the natural course 
of submacular hemorrhage is poor.
The Submacular Surgery Trial investigated 
AMD patients with SMH and reported decrease 
of two or more lines in VA in 64% of eyes with 
untreated SMH after 36 months of follow-up, as 
compared to 51% of eyes undergoing mechanical 
removal of the underlying CNV and SMH by 
pars plana vitrectomy.20 No significant difference 
in VA was observed between the treated and 
non-treated groups.
Heriot21 first described management of 
submacular hemorrhage with intravitreal 
rtPA injection and pneumatic displacement 
of blood from the fovea. His initial experience 
suggested a high anatomic success rate with 
few complications. Other reports subsequently 
confirmed the capability of an intravitreal gas 
bubble, with or without intravitreal rtPA, to 
displace thick blood from beneath the fovea 
in most eyes. This office-based procedure 
was simpler, less costly and less traumatic 
to photoreceptors and the retinal pigment 
epithelium as compared to surgical evacuation 
of subretinal blood.22 In a large series involving 
52 cases, Chen et al23 demonstrated improvement 
of two Snellen lines or more, 3 months after 
rtPA and expansile gas injection. In another 
study, Regillo24 demonstrated that submacular 
blood was completely displaced from the fovea 
in 10 (71%) of 14 eyes and partially displaced 
in three (21%) eyes after intravitreal injection 
of rtPA and expansile gas. In one patient, no 
displacement occurred. Early postoperative VA 
(within 2 months) improved by two or more 
lines in eight eyes (57.1%). However, with a 
longer mean follow-up of 7.7 months, only 2 
of the 14 eyes (14.2%) maintained 2 or more 
lines of improvement. No clinical evidence of 
retinal toxicity was seen.
Previously, additional intervention with 
photodynamic therapy (PDT) was employed 
if the SMH was shifted successfully from the 
fovea and the underlying CNV became visible. 
Bakri et al25 reported patients with subretinal 
hemorrhage who were noted to have foveal 
involvement due to neovascular AMD. Mean 
initial visual acuity was 20/372 which reached 
20/227 twelve months after PDT treatment. The 
difference in VA was not statistically significant.
Antiangiogenic agents have opened a new 
approach toward effective and early treatment 
of choroidal neovascularization. The consecutive 
application of antiangiogenic agents treats the 
CNV which is the underlying cause of SMH. 
Stifter et al26 evaluated the effectiveness and 
safety of intravitreal bevacizumab alone, 
without displacement of the SMH, for large 
submacular hemorrhages in neovascular AMD, 
and reported visual stabilization in all eyes. 
Visual improvement of one line or more, and 
three lines or more was achieved in 38% and 
9.5% of eyes, respectively.
Meyer et al27 reported that injection 
of intravitreal rtPA, expansile gas, and 
bevacizumab was successful in achieving 
anatomical displacement of the SMH. Mean 
VA improvement was 2.1 lines and 3.7 ETDRS 
chart lines 1 and 3 months after treatment, 
respectively.
In the present series, intravitreal expansile 
gas injection, with or without intravitreal rtPA 
injection, was successful in achieving anatomic 
displacement of submacular blood. There has 
been some doubt regarding the role of rtPA in 
the management of SMH, in particular, whether 
intravitreal rtPA can access the subretinal 
space in sufficient quantities to induce clot 
liquefaction. There are several small clinical 
series to suggest that a gas bubble alone is 
enough to displace submacular blood and the 
role of rtPA remains uncertain. It has been 
shown that albumin, a protein comparable 
in molecular size to rtPA, can diffuse across 
the intact retina. Furthermore, tenecteplase, a 
synthetic variant of rtPA with almost identical 
molecular weight and size, has been shown 
to be able to penetrate through all layers of 
the retina following intravitreal injection in 
a porcine model.28 Further clinical and basic 
science investigations are required to elucidate 
the role of rtPA in this technique.Expansile Gas and IVB for SMH; Nourinia et al
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Expansile gas and rtPA physically shift 
the SMH away from the fovea and minimize 
scar formation. Anti-VEGF treatment can be 
given prior to, or simultaneous with pneumatic 
displacement of the submacular hemorrhage. 
Meyer et al27 used intravitreal bevacizumab 
simultaneously with intravitreal rtPA and SF6, 
but we used intravitreal bevacizumab after 
pneumatic displacement of the submacular 
hemorrhage. More studies are needed to 
identify the preferred timing of intravitreal 
bevacizumab in these cases.
In summary intravitreal expansile gas 
injection, with or without recombinant tissue 
plasminogen activator, followed by intravitreal 
bevacizumab injection seems to result in visual 
improvement in eyes with SMH secondary to 
neovascular AMD which may otherwise have 
a poor visual outcome.
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